Anupam Rama
Stock Analyst at JP Morgan
(3.40)
# 917
Out of 4,784 analysts
261
Total ratings
41.31%
Success rate
4.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $38.89 | +200.85% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $114.00 | +61.40% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $36.40 | +37.36% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $13.56 | +202.36% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $36.18 | +40.96% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $4.37 | +151.72% | 7 | Mar 13, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $39 → $34 | $8.19 | +315.14% | 4 | Mar 5, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $36 → $42 | $18.65 | +125.20% | 11 | Mar 5, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $77 → $71 | $26.52 | +167.72% | 9 | Mar 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $50 → $54 | $24.28 | +122.41% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $20.37 | +116.00% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $10.45 | +72.25% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $6.29 | +249.76% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.27 | +166.19% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $21 | $6.61 | +217.70% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $8.59 | +97.90% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.42 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $23.36 | +71.23% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $73.62 | +69.79% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.94 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $47.49 | +43.19% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $31 | $4.20 | +638.10% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $17.43 | +278.66% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $8.66 | +15.47% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.71 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $71.81 | +143.70% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $0.62 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.24 | +480.36% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.46 | +1,869.80% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.06 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.26 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $6.88 | +3,533.72% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.41 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $42.99 | +34.92% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $9.31 | +28.89% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $6.67 | +454.72% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $49.46 | +11.20% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.55 | +1,706.45% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $30.84 | +75.10% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.39 | +11,362.05% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $11.80 | +128.81% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $6.71 | +496.57% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $271.02 | -49.45% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.96 | +686.29% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $5.11 | +839.33% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $13.72 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $1.03 | +1,647.57% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.25 | +2,300.00% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $54.99 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.46 | - | 2 | Jul 21, 2017 |
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $38.89
Upside: +200.85%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $114.00
Upside: +61.40%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $36.40
Upside: +37.36%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $13.56
Upside: +202.36%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $36.18
Upside: +40.96%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.37
Upside: +151.72%
Day One Biopharmaceuticals
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $8.19
Upside: +315.14%
AnaptysBio
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $18.65
Upside: +125.20%
Vera Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $26.52
Upside: +167.72%
Apellis Pharmaceuticals
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $24.28
Upside: +122.41%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $20.37
Upside: +116.00%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $10.45
Upside: +72.25%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $6.29
Upside: +249.76%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $11.27
Upside: +166.19%
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $6.61
Upside: +217.70%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $8.59
Upside: +97.90%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.42
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $23.36
Upside: +71.23%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $73.62
Upside: +69.79%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $0.94
Upside: -
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $47.49
Upside: +43.19%
Aug 8, 2024
Maintains: Overweight
Price Target: $33 → $31
Current: $4.20
Upside: +638.10%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $17.43
Upside: +278.66%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $8.66
Upside: +15.47%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.71
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $71.81
Upside: +143.70%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $0.62
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.24
Upside: +480.36%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.46
Upside: +1,869.80%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.06
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.26
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $6.88
Upside: +3,533.72%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.41
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $42.99
Upside: +34.92%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $9.31
Upside: +28.89%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $6.67
Upside: +454.72%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $49.46
Upside: +11.20%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.55
Upside: +1,706.45%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $30.84
Upside: +75.10%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.39
Upside: +11,362.05%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $11.80
Upside: +128.81%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $6.71
Upside: +496.57%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $271.02
Upside: -49.45%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.96
Upside: +686.29%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $5.11
Upside: +839.33%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $13.72
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $1.03
Upside: +1,647.57%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.25
Upside: +2,300.00%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $54.99
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -